| Similar Articles |
|---|
 |
The Motley Fool
April 11, 2011
Brian Orelli |
Clinical Trial Fail? Forget About It. A failure of Medivation and Pfizer's dimebon was expected.   |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
September 5, 2008
Brian Lawler |
Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon. |
The Motley Fool
January 17, 2012
Brian Orelli |
You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again. |
The Motley Fool
January 13, 2010
Brian Orelli |
JPMorgan Challenge: On the Cusp of Greatness Development-stage drugmaker Medivation has a partner and is ready for phase 3 data to roll in. |
The Motley Fool
March 11, 2010
Jim Mueller |
Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices? |
The Motley Fool
March 4, 2011
Brian Orelli |
Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors. |
The Motley Fool
May 28, 2010
Brian Orelli |
Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree. |
The Motley Fool
June 18, 2008
Brian Lawler |
Elan's and Wyeth's Data: Success or Failure? Elan and partner Wyeth released new mid-stage data for their potential blockbuster bapineuzumab (AAB-001) for Alzheimer's disease, but the results aren't conclusive. |
The Motley Fool
January 12, 2005
Charly Travers |
Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity. |
The Motley Fool
August 17, 2010
Brian Orelli |
Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard. |
The Motley Fool
November 8, 2010
Brian Orelli |
No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective. |
The Motley Fool
March 1, 2007
Brian Lawler |
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. |
The Motley Fool
July 31, 2008
Brian Lawler |
Examining Elan's Ups and Downs Was the pharmaceutical's news about its potential Alzheimer's treatment as bad as investors treated it? |
The Motley Fool
December 31, 2011
Brian Orelli |
3 More Stock-Moving Binary Events to Watch in 2012 There are a lot of drugs that will face binary events in 2012 -- here are three to watch. |
The Motley Fool
August 31, 2009
Brian Orelli |
Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it.. |
The Motley Fool
October 8, 2010
Brian Orelli |
Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size. |
The Motley Fool
February 8, 2005
Charly Travers |
Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
March 17, 2006
Rich Duprey |
Eisai's Dementia Problems Clinical trials for expanded use of the Japanese pharma's top-selling drug reveal higher incidences of death. Aricept is already approved for vascular dementia in several countries, but it would seem that FDA approval for use here won't be coming any time soon. Investors, take note. |
The Motley Fool
November 9, 2010
Brian Orelli |
Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals. |
The Motley Fool
July 29, 2009
Brian Orelli |
Ignore These Companies at Your Peril You may not want to invest in them, but don't ignore them. |
The Motley Fool
May 22, 2007
Brian Lawler |
Elan Plunges Ahead Shares of the drugmaker Elan have climbed more than 20% in the past two days after the company announced that it and partner Wyeth were moving their lead Alzheimer's disease treatment into phase 3 testing. |
The Motley Fool
January 25, 2007
Brian Lawler |
Renovis Tries to Right Itself Renovis takes some steps to try and recover after its lead drug fails in clinical testing. Investors, take note. |
The Motley Fool
June 5, 2009
Brian Orelli |
Failure! Merck said today that rolofylline failed to show an effect in its phase 3 clinical trial in heart failure patients. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
August 13, 2007
Rich Duprey |
U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept. |
The Motley Fool
March 30, 2009
Brian Orelli |
Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
The Motley Fool
October 26, 2004
Charly Travers |
Biotech's 5-Baggers: Part 2 Several hot drugs are generating smoking returns. If the goal for an investor is to aim for one of these five-baggers, then one option is to invest before the company passes through the inflection point. |
The Motley Fool
September 1, 2004
W.D. Crotty |
A Pall Falls Over Forest One of Forest Labs' Alzheimer's drugs fails in phase 3 trials. For investors willing to take the political risk, today's drug news has taken a battered stock, with a great balance sheet, to very reasonable price levels. |
The Motley Fool
May 4, 2010
Brian Orelli |
Earnings Growth Trumps Revenue Growth, Except Here A solid quarter for Pfizer, but is there more in the tank? |
The Motley Fool
September 20, 2007
Brian Orelli |
Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note. |
The Motley Fool
December 15, 2009
Brian Orelli |
Forget the Higher Doses Elan has to drop the highest dose of an Alzheimer's drug. Again. |
The Motley Fool
September 30, 2005
Stephen D. Simpson |
Two Pharma Trees Fall The news of a phase 3 trial failure hammers both Forest Labs and Cypress Bioscience. Investors, take note. |
The Motley Fool
April 17, 2007
Rich Duprey |
Eisai Says Sayonara The Japanese company withdraws its application for approval of its Alzheimer's drug for severe cases of the disease in Europe. What will it mean to investors? |
The Motley Fool
October 24, 2006
Brian Lawler |
Playing the AtheroGenics Waiting Game The results of phase 3 trials for the company's atherosclerosis drug will determine AtheroGenics' future. Investors, take note. |
The Motley Fool
January 17, 2008
Brian Orelli |
EPIX's Epic Oops The EPIX clinical trial data on their Alzheimer's medication wasn't as positive as it first appeared. |
Chemistry World
August 9, 2012 |
Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials. |
The Motley Fool
April 3, 2009
Brian Orelli |
Toning Down a Treatment Elan and Wyeth drop the highest dose of their Alzheimer's drug. |
The Motley Fool
September 27, 2007
Brian Orelli |
Incyte's Double Dose of Trial News With two drugs providing good results in preliminary trials, and another five medications in early-stage clinicals, Incyte is a shining example of a developmental-stage drugmaker. Investors, take note. |
The Motley Fool
December 19, 2008
Brian Orelli |
Open-Label Bites Drug Duo Pfizer and Celldex have to make the best of a bad situation. |
The Motley Fool
April 3, 2009
Brian Orelli |
Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
January 24, 2005
Rich Duprey |
No Taking Chances With Reminyl Johnson & Johnson's daffodil-extract Alzheimer's treatment yanked from market. Shares are off only 1% or so. |
The Motley Fool
November 2, 2006
Rich Duprey |
Eisai Profits From Demand The Japanese pharmaceutical reports strong profits on increased demand for Alzheimer's treatment. Investors, take note. |
The Motley Fool
June 29, 2007
Rich Duprey |
No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment. |
The Motley Fool
September 7, 2007
Brian Orelli |
Clinical Data Gets Personal Clinical Data's lead compound Vilazodone posts strong phase 3 results. The company is searching for common genetic markers among patients who responded positively to the drug. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
